SCHEMBL19557697

SCHEMBL19557697

BC(C)(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2cc(C)c(C3CCNCC3)cc2OC(C)C)ncc1Cl

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 18/20 0.82
INSR P06213 9/20 0.82
KCNH2 Q12809 3/20 0.82
EGFR P00533 2/20 0.82
PLK4 O00444 1/20 0.82
BUB1B O60566 1/20 0.82
JAK2 O60674 1/20 0.82
ROCK2 O75116 1/20 0.82
ABL1 P00519 1/20 0.82
NTRK1 P04629 1/20 0.82
LCK P06239 1/20 0.82
NPM1 P06748 1/20 0.82
FES P07332 1/20 0.82
LYN P07948 1/20 0.82
RET P07949 1/20 0.82
IGF1R P08069 1/20 0.82
ABCB1 P08183 1/20 0.82
MET P08581 1/20 0.82
ROS1 P08922 1/20 0.82
FGR P09769 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19557686 0.94 ALK (0.80) ALKINSRKCNH2EGFRPLK4
SCHEMBL19870462 0.94 ALK (0.85) ALKINSRKCNH2EGFRPLK4
SCHEMBL21169740 0.93 ALK (0.82) ALKINSRKCNH2EGFRPLK4
SCHEMBL19557702 0.92 ALK (0.70) ALKINSRKCNH2EGFRPLK4
SCHEMBL21169756 0.92 ALK (0.76) ALKINSRKCNH2EGFRPLK4
SCHEMBL21170018 0.91 ALK (0.80) ALKINSRKCNH2EGFRPLK4
SCHEMBL23637757 0.91 ALK (0.87) ALKINSRKCNH2EGFRPLK4
SCHEMBL21170024 0.91 ALK (0.69) ALKINSRKCNH2EGFRPLK4
Ceritinib SCHEMBL29349781 0.90 ALK (1.00) ALKINSRKCNH2EGFRPLK4
SCHEMBL21169823 0.90 ALK (0.86) ALKINSRKCNH2EGFRPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10618884-B2 Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) 2020-04-14 US disclosed
US-20180044323-A1 DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS SUZHOU ZELGEN BIOPHARMACEUTICALS CO LTD (CN) 2018-02-15 US disclosed
US-9809572-B2 Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) 2017-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10618884-B2 Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds DCK, DPYD, BRAF ALK 1210/4885INSR 2231/4885KCNH2 2496/4885
US-20180044323-A1 DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS DCK, DPYD, BRAF ALK 1210/4885INSR 2231/4885KCNH2 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.